Thermo Fisher Scientific has expanded its range of mass spectrometers for clinical diagnostic laboratories with the addition of two systems now listed as Class I medical devices with the United States Food and Drug Administration (US FDA): the Thermo Scientific TSQ Altis MD Series and the Thermo Scientific Quantis MD Series. The analytical solutions are designed to provide confidence in laboratory developed tests (LDTs) through a complete suite of LDT-enabled software with a laboratory information system (LIS) option. In addition, the enhanced product portfolio is designed to increase throughput of clinical diagnostic assays for the detection of small to large molecules within complex biological matrices. The TSQ Altis MD Series and TSQ Quantis MD Series mass spectrometers offer similar throughput for the analysis of human samples, but differ by sensitivity. The MD portfolio uses Thermo Scientific TraceFinder LDT 1.0 Software. Included as standard, the software provides a workflow-oriented approach to high-throughput quantitation, including an administrator console for managing user-based permissions, data repositories and auditing capabilities. In addition, an optional middleware solution is available to provide bidirectional communication between TraceFinder LDT Software and the LIS.